CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project focuses on the development of Nanobodies as novel therapeutic agents targeting immune checkpoint complexes. By modulating immune signaling pathways, the research aims to improve treatments for cancer and autoimmune diseases.
The fastidious balance of our immune system to fight infections or cancer while avoiding autoimmune reactions is regulated by coinhibitory and co-stimulatory immune checkpoint complexes (ICCs), which have become major drug targets.
We witness the skyrocketing progression in cancer immunotherapy with antibodies that block inhibitory ICCs whereas Abs that block stimulatory ICCs are in clinical trials for treating autoimmune diseases.Surprisingly, but likely fuelled by the most obvious focus on IC…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
